Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: Analysis of the multicenter clinical trial AML-BFM 93

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 10, 2007, Pages 735-738

  Lehrnbecher, T ^a   Kaiser, J ^a   Varwig, D ^a   Ritter, J ^b   Groll, A H ^b   Creutzig, U ^b   Klingebiel, T ^a   Schwabe, D ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; IDARUBICIN; ITRACONAZOLE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; DOSE RESPONSE; DRUG USE; EDUCATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; FEMALE; FLUCONAZOLE; FLUCYTOSINE; HUMANS; INFANT; INFANT, NEWBORN; ITRACONAZOLE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; RETROSPECTIVE STUDIES;

EID: 34548484364     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0362-9     Document Type: Article

References (15)

1. Riley LC, Hann IM, Wheatley K, Stevens RF (1999) Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 106:436-444
2. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T (2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384-4393
3. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U (2004) Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 18:72-77
4. Cesaro S, Strugo L, Alaggio R, Cecchetto G, Rigobello L, Pillon M, Cusinato R, Zanesco L (2003) Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer 11:722-727
5. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB (2005) Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 27:135-140
6. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
7. Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wormann B, Buchner T, Hiddemann W (1998) Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 83:291-301
8. Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39 Suppl 1:S11-S14
9. Martin MT, Gavalda J, Lopez P, Gomis X, Ramirez JL, Rodriguez D, Len O, Jordano Q, Ruiz I, Rosal M, Almirante B, Pahissa A (2003) Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 52:1032-1034
10. Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, Bearden DT (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. DOI 10.1002/pds.1365
11. Perfect J, Klotman M, Gilbert C, Crawford D, Rosner G, Wright K et al (1992) Prophylactic intravenous amphotericin B in neutropenic autologous marrow transplant recipients. J Infect Dis 165:891-897
12. Baddley JW, Pappas PG (2005) Antifungal combination therapy: clinical potential. Drugs 65:1461-1480
13. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
14. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ (2006) Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711-e716
15. Zaoutis TE, Prasad P-A, Heydon KH, Walsh TJ (2006) The utilization of antifungals in 26 United States children's hospitals. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no M-905